Isomorphic Labs: AI-Designed Drugs Poised for Human Trials

Alphabet's Isomorphic Labs, a secretive drug discovery arm, is on the verge of human clinical trials for its AI-designed drugs. Leveraging DeepMind's AlphaFold technology, the company can accurately predict protein structures and model their interactions, significantly accelerating drug development. Isomorphic Labs has partnered with pharmaceutical giants like Novartis and Eli Lilly, securing $600 million in funding to build a world-class drug design engine. Their aim is to dramatically improve the success rate of drug discovery, ultimately envisioning a future where drug design is as simple as clicking a button.